Pharmaceutical Export Opportunities from Bangladesh to Brazil

A Complete Step-by-Step Guide

 

Md. Joynal Abdin
Business Consultant | Entrepreneur | International Trade Specialist
Founder & Chief Executive Officer, Trade & Investment Bangladesh (T&IB)
Secretary General, Brazil Bangladesh Chamber of Commerce & Industry (BBCCI)

 

Bangladesh has developed one of the most competitive pharmaceutical manufacturing industries among emerging economies. From a domestic market once heavily dependent on imported medicines, the country has transformed into a significant producer of generic medicines, specialized pharmaceutical products, active pharmaceutical ingredients, and increasingly sophisticated formulations. According to the Bangladesh Association of Pharmaceutical Industries, the local pharmaceutical industry meets approximately 98% of Bangladesh’s domestic medicine requirements and exports pharmaceutical products to more than 150 countries. Leading Bangladeshi manufacturers have also obtained international regulatory and GMP approvals, including certifications associated with markets such as the United States, United Kingdom, European Union, Australia, Canada and Brazil.

 

Brazil represents a particularly attractive but demanding destination for Bangladeshi pharmaceutical exporters. With more than 200 million consumers, a large public healthcare system, an established private healthcare market and substantial demand for generic and affordable medicines, Brazil offers considerable opportunities for manufacturers capable of meeting its strict regulatory standards. Brazil’s regulated pharmaceutical market generated approximately R$160.7 billion in revenue in 2024, representing nominal growth of 12.9% compared with 2023. Around 6.07 billion medicine packages were sold during the year. The market included 232 companies, 7,289 commercial product names, 514 therapeutic classes and 1,944 active ingredients.

 

For Bangladeshi pharmaceutical companies, therefore, Brazil should not simply be viewed as another export destination. It should be approached as a strategic long-term market requiring regulatory preparation, appropriate Brazilian partnerships, disciplined product selection and substantial investment in registration and market development. This guide explains how to export pharmaceuticals from Bangladesh to Brazil step by step, from preliminary market research to ANVISA registration, importer appointment, pricing, shipment and long-term market development.

 

Why Brazil Is an Attractive Pharmaceutical Market?

Brazil possesses one of the largest healthcare systems and pharmaceutical consumer markets in Latin America. Demand is supported by population size, demographic changes, chronic diseases, expansion of healthcare access and continuous consumption of prescription and over-the-counter medicines. The country also has an established market for generic medicines. Brazil’s regulatory framework recognizes generic medicines based on pharmaceutical equivalence and bioequivalence requirements. ANVISA states that generic products must contain the same active ingredient, strength, dosage form, route of administration, therapeutic indication and comparable efficacy and safety to the relevant reference medicine.

 

This creates opportunities for efficient generic manufacturers from Bangladesh. Potential product categories include:

• cardiovascular medicines;
• anti-diabetic drugs;
• antibiotics and anti-infective products;
• gastrointestinal products;
• respiratory medicines;
• analgesics and anti-inflammatory medicines;
• dermatological preparations;
• oncology medicines;
• hormonal products;
• selected injectable products;
• hospital medicines;
• nutritionally related pharmaceutical preparations;
• selected APIs and pharmaceutical inputs.

 

However, exporters should never select products merely because they sell well in Bangladesh. Brazil has its own regulatory classifications, prescribing practices, reference products, pricing environment and competition. A product-by-product feasibility study should therefore precede registration.

 

Step 1: Conduct Pharmaceutical Market Research in Brazil

The first step toward pharmaceutical exports to Brazil is professional market research. Before approaching distributors or filing regulatory applications, manufacturers should identify which products have realistic commercial opportunities. Research should evaluate:

Market demand: Determine annual consumption and historical growth for the relevant molecule or therapeutic class.

 

Competition: Identify Brazilian manufacturers, multinational brands, generic competitors and imported alternatives.

 

Retail pricing: Study retail, distributor and institutional prices.

 

Regulatory status: Verify available reference products, generic registrations and regulatory category.

 

Import dependence: Products where Brazil relies significantly on foreign supply may offer better entry opportunities.

 

Patent position: Patent and data exclusivity considerations should be investigated before registration or commercialization.

 

Distribution structure: Determine whether products are primarily sold through retail pharmacies, hospitals, healthcare networks, government procurement or specialist distributors.

 

Brazilian pharmaceutical market information available through ANVISA and the Câmara de Regulação do Mercado de Medicamentos CMED can provide valuable insight into market structure and registered products. Bangladeshi exporters should initially develop a shortlist of perhaps 10–20 potentially competitive products, rather than attempting registration of an unnecessarily large portfolio.

 

Step 2: Select the Right Pharmaceutical Products

Product selection is one of the most important strategic decisions. A medicine may be successful in Bangladesh yet commercially unattractive in Brazil because of regulatory costs, price competition or market saturation.

 

Products should ideally satisfy several criteria:

1. substantial Brazilian demand;
2. sufficient profit margin;
3. manageable regulatory requirements;
4. competitive manufacturing cost in Bangladesh;
5. strong stability profile;
6. appropriate production capacity;
7. limited patent barriers;
8. availability of necessary bioequivalence or clinical documentation.

 

Generic medicines can be particularly attractive because Bangladesh has developed substantial expertise in cost-efficient generic production. Bangladeshi manufacturers may also explore niche medicines where relatively fewer suppliers operate, rather than competing exclusively in highly commoditized molecules.

 

Step 3: Understand ANVISA

The central institution governing medicines in Brazil is the Agência Nacional de Vigilância Sanitária (ANVISA), Brazil’s National Health Surveillance Agency. Any Bangladeshi pharmaceutical company seriously considering Brazil must understand that pharmaceutical market access is fundamentally a regulatory project before it becomes a sales project.

 

ANVISA regulates areas including:

• pharmaceutical company authorization;
• medicine registration;
• manufacturing quality;
• good manufacturing practices;
• pharmaceutical imports;
• labeling;
• post-market surveillance;
• controlled substances;
• biological products;
• APIs and related products.

 

Current general requirements for regularization of human medicines are governed, among other rules, by RDC 948/2024, while individual regulatory categories may be subject to additional rules and guidance. Companies should therefore engage experienced Brazilian regulatory specialists before investing heavily in a product registration program.

Step 4: Appoint a Qualified Brazilian Partner

A Bangladeshi pharmaceutical manufacturer generally cannot independently conduct the complete Brazilian regulatory and commercial process from Bangladesh. A qualified Brazilian company must typically serve as the local regulatory and commercial partner. ANVISA specifically states that foreign manufacturers cannot directly handle the GMP certification process with the agency; they require a company legally established in Brazil to act as their local representative and assume responsibility for imported products.

 

Therefore, identifying the right partner is critical. Potential partners include:

• pharmaceutical importers;
• pharmaceutical distributors;
• Brazilian pharmaceutical companies;
• regulatory representatives;
• licensing partners;
• marketing authorization partners.

 

The Brazilian importing organization must possess the necessary authorizations. ANVISA’s Autorização de Funcionamento de Empresa (AFE) is required for activities including importing, distributing, storing, manufacturing, exporting, transporting and packaging medicines or pharmaceutical inputs.

 

Before appointing any company, conduct commercial due diligence. Verify:

• ANVISA authorizations;
• company registration;
• regulatory track record;
• warehousing facilities;
• geographic distribution;
• sales team;
• hospital and pharmacy relationships;
• financial capability;
• product portfolio;
• litigation history;
• reputation;
• experience with imported pharmaceuticals.

 

Do not appoint a distributor based solely on an attractive introductory email or promises of large orders.

 

Step 5: Negotiate the Commercial and Regulatory Agreement

Once a capable partner is identified, both parties should establish contractual responsibilities. The agreement should clearly identify who will pay for:

• ANVISA registration;
• GMP certification;
• dossier preparation;
• translations;
• bioequivalence studies;
• analytical testing;
• sample shipments;
• inspections;
• registration maintenance;
• local marketing;
• pharmacovigilance.

 

Another critical issue is ownership and control of registrations. Bangladeshi companies should obtain professional legal advice regarding arrangements for product registrations, trademarks and distribution rights. Losing control of regulatory or intellectual-property assets may create serious problems if the relationship with the Brazilian distributor later deteriorates.

 

Distribution agreements should additionally address:

• sales territory;
• exclusivity;
• minimum annual purchases;
• sales targets;
• payment terms;
• contract duration;
• termination rights;
• confidentiality;
• trademark ownership;
• non-performance;
• product recalls;
• pharmacovigilance responsibilities.

 

Exclusivity should normally be linked to measurable performance.

 

Step 6: Obtain ANVISA GMP Certification

Manufacturing quality approval is a central requirement. ANVISA performs international GMP oversight of foreign manufacturers supplying medicines and APIs to Brazil. A valid Certificado de Boas Práticas de Fabricação (CBPF), or Good Manufacturing Practices Certificate, is a prerequisite for marketing authorization for relevant pharmaceutical products in Brazil.

 

The Brazilian representative normally files the relevant petition. ANVISA may assess documentation and, depending on its risk evaluation and applicable procedures, may conduct inspections.

 

Therefore, Bangladeshi factories planning Brazilian entry should maintain strong compliance in areas such as:

• pharmaceutical quality systems;
• validation;
• documentation;
• laboratory control;
• data integrity;
• deviation management;
• CAPA;
• cleaning validation;
• process validation;
• stability testing;
• supplier qualification;
• batch release;
• change control.

 

Manufacturers already accustomed to USFDA, EU GMP, UK MHRA, TGA or other stringent regulatory inspections may have an operational advantage, although Brazilian requirements must still be independently satisfied.

 

Step 7: Prepare the Pharmaceutical Registration Dossier

The technical dossier is the foundation of product registration. Depending upon the product category, regulatory submissions may require extensive information concerning:

• active pharmaceutical ingredient;
• formulation;
• manufacturing process;
• specifications;
• analytical methods;
• validation;
• stability;
• packaging materials;
• finished-product testing;
• pharmaceutical development;
• safety;
• efficacy;
• bioequivalence;
• labeling.

 

For generic products, pharmaceutical equivalence and bioequivalence are particularly important because they establish comparability with the recognized reference medicine. Exporters should establish a dedicated Brazil regulatory project team involving regulatory affairs, quality assurance, research and development, production, international marketing and legal personnel.

Poorly prepared dossiers can cause regulatory queries, delays and substantial additional expense.

 

Step 8: Prepare Portuguese Documentation and Labeling

Brazil’s official language is Portuguese. Pharmaceutical exporters should therefore plan for professional Brazilian Portuguese translation of regulatory and commercial materials. Labels, package inserts and patient information must comply with Brazilian requirements.

 

Translation should never be treated as routine general translation. Pharmaceutical terminology requires technical accuracy. Professional regulatory translators should understand:

• medicine terminology;
• dosage instructions;
• contraindications;
• adverse reactions;
• warnings;
• storage conditions;
• manufacturing details;
• regulatory terminology.

 

Translation errors can become regulatory as well as patient-safety problems.

Step 9: Complete Medicine Registration

Once regulatory prerequisites are satisfied, the Brazilian applicant submits the medicine registration application through the relevant ANVISA process. ANVISA currently provides separate procedures covering new medicines, generic medicines, biological products and other regulated categories. Applications may generate technical questions requiring supplementary documents or clarification.

 

Exporters should therefore maintain rapid internal response mechanisms. Regulatory success depends not only on submission but on responding professionally and quickly throughout the review process.

 

Companies should budget adequate time and resources because pharmaceutical registration is fundamentally different from exporting ordinary consumer products.

 

Step 10: Study Brazil’s Pharmaceutical Pricing Rules

Brazil has regulated medicine pricing. The Câmara de Regulação do Mercado de Medicamentos (CMED) plays a central role in pharmaceutical price regulation. Therefore, exporters cannot simply calculate: Manufacturing Cost + Freight + Importer Margin + Retailer Margin = Brazilian Selling Price.

 

Regulatory pricing constraints must also be considered. This is particularly relevant for generic medicines, where competition may be strong. ANVISA notes that Brazilian generic policy has historically required generic products to be priced below their reference counterparts, reinforcing affordability and market competition.

 

Before product registration, exporters should therefore conduct a complete profitability model covering:

• ex-factory price;
• regulatory expenses;
• import duties where applicable;
• federal taxes;
• state taxes;
• freight;
• insurance;
• customs expenses;
• warehousing;
• distributor margin;
• pharmacy margin;
• marketing expenditure;
• currency fluctuation.

 

Brazil’s official import treatment simulator can be used to check applicable administrative requirements and ad valorem taxes according to a product’s NCM classification.

 

Step 11: Prepare Export Documentation in Bangladesh

Once regulatory approvals and a confirmed commercial order are in place, the exporter must complete normal Bangladesh export procedures as well as pharmaceutical-specific requirements.

Depending on the transaction, documentation may include:

• commercial invoice;
• packing list;
• export contract or purchase order;
• EXP documentation;
• certificate of origin;
• bill of lading or airway bill;
• insurance certificate;
• certificate of analysis;
• batch release certificate;
• GMP certificate;
• free sale certificate where applicable;
• pharmaceutical product certificate where applicable;
• relevant DGDA documentation;
• regulatory documents requested by the Brazilian importer.

 

Requirements depend on product type, shipment terms and Brazilian import procedures. Exporters should coordinate closely with their nominated bank, customs agent, freight forwarder, DGDA-related regulatory personnel and Brazilian importer.

 

Step 12: Arrange Pharmaceutical Logistics

Pharmaceutical logistics must preserve product quality throughout transportation. Key factors include:

 

Temperature: Products requiring controlled temperature must remain within validated ranges.

 

Humidity: Moisture-sensitive products require proper packaging and container management.

 

Transit time: Long transit routes increase stability risks and working-capital requirements.

 

Packaging: Export cartons should withstand international transportation.

 

Data loggers: Temperature-sensitive shipments may require monitoring devices.

 

Insurance: Cargo should carry adequate insurance.

 

High-value or temperature-sensitive pharmaceutical shipments may justify airfreight, while stable high-volume generic products can potentially move by sea. São Paulo and other major Brazilian commercial centers can serve as important distribution gateways depending upon the importer’s logistics infrastructure.

 

Step 13: Select Appropriate Incoterms and Payment Terms

For initial pharmaceutical transactions, payment security should receive high priority. Possible arrangements include:

• irrevocable Letter of Credit;
• confirmed Letter of Credit;
• advance payment;
• documentary collection for established buyers;
• open-account arrangements only after substantial business history.

 

Suitable Incoterms may include:

• FOB;
• CFR;
• CIF;
• FCA;
• CIP.

 

The appropriate structure depends on transport mode and contractual responsibility. Bangladeshi exporters should avoid granting substantial unsecured credit to unfamiliar overseas distributors before satisfactory due diligence and transaction history.

 

Step 14: Develop Pharmaceutical Distribution Channels

Receiving regulatory approval does not automatically generate sales. Brazil is geographically enormous and pharmaceutical distribution is sophisticated.

 

Possible channels include:

• national pharmaceutical distributors;
• regional distributors;
• pharmacy chains;
• hospitals;
• healthcare institutions;
• specialist clinics;
• private healthcare groups;
• government procurement;
• institutional tenders.

 

Exporters should determine which channel suits each product category. A hospital injectable, for example, requires a completely different commercial strategy from a mass-market oral generic.

 

Step 15: Build Relationships with Brazilian Healthcare Stakeholders

Successful pharmaceutical exports depend on relationships as well as regulatory approvals.

Bangladeshi companies should consider participating in:

• pharmaceutical exhibitions;
• healthcare trade shows;
• Bangladesh–Brazil business delegations;
• pharmaceutical conferences;
• B2B meetings;
• importer-distributor matchmaking programs;
• embassy-supported business events;
• chamber networking programs.

 

Companies should arrange structured meetings with potential Brazilian pharmaceutical importers, distributors, manufacturers and institutional buyers. Brazil should be approached as a long-term strategic market rather than a destination for occasional spot shipments.

Challenges Bangladeshi Pharmaceutical Exporters Should Anticipate

Brazil offers considerable opportunity but market entry is demanding. Major challenges include:

 

Regulatory complexity: ANVISA maintains stringent requirements.

 

Language: Regulatory documentation and commercial communication frequently require Portuguese.

 

Registration cost: Product registration, studies, translations and regulatory support require investment.

 

Long market-development cycle: Pharmaceutical exports typically require months or years of preparation.

 

Domestic competition: Brazil has established local and multinational pharmaceutical manufacturers.

 

Price pressure: Generic medicines face strong competition.

 

Distance: Bangladesh–Brazil logistics are longer than regional Asian routes.

 

These challenges should not discourage serious exporters. They simply demonstrate why Brazil requires a structured strategy.

 

Recommended Market-Entry Strategy for Bangladeshi Companies

A practical Brazilian pharmaceutical entry strategy can follow this sequence:

 

Phase 1 – Research

Identify 10–20 promising molecules.

 

Phase 2 – Shortlisting

Reduce the list to perhaps 5–10 commercially attractive products.

 

Phase 3 – Partner Search

Identify qualified Brazilian importers, distributors or pharmaceutical licensing partners.

 

Phase 4 – Due Diligence

Verify regulatory, commercial and financial capability.

 

Phase 5 – Regulatory Gap Analysis

Compare factory and product documentation against ANVISA requirements.

 

Phase 6 – GMP Process

Initiate necessary Brazilian GMP certification procedures.

 

Phase 7 – Registration

Prepare and submit selected product dossiers.

 

Phase 8 – Commercial Preparation

Determine pricing, branding, distribution strategy and sales forecasts.

 

Phase 9 – Pilot Launch

Launch selected registered products with measurable sales targets.

 

Phase 10 – Portfolio Expansion

Register additional products after establishing distribution capability.

 

This incremental approach can reduce risk and prevent companies from committing excessive resources before understanding Brazilian market dynamics.

 

Competitive Advantages of Bangladesh

Bangladesh possesses several important advantages. First, production costs can be competitive.

Second, the country has extensive experience manufacturing generic medicines. Third, its pharmaceutical industry already produces sophisticated products including insulin, hormones and anti-cancer medicines. BAPI states that the sector supplies approximately 98% of Bangladesh’s domestic medicine demand while exporting to more than 150 countries. Fourth, several leading manufacturers have experience with stringent international regulatory environments.

 

Therefore, Bangladesh has the technical foundation necessary to become a stronger pharmaceutical supplier to Latin America. Brazil can potentially serve not only as a final destination but also as a strategic gateway for deeper engagement with the South American pharmaceutical market.

 

Conclusion

The opportunities for pharmaceutical exports from Bangladesh to Brazil are substantial, but success will depend on preparation rather than simply competitive pricing. Brazil’s pharmaceutical market exceeded R$160 billion in sales in 2024, with more than six billion packages sold, illustrating the sheer scale of commercial opportunity. Bangladeshi manufacturers already possess many essential competitive strengths: cost-effective manufacturing, extensive generic production experience, growing regulatory sophistication and an export footprint covering more than 150 countries.

 

The next challenge is to convert those strengths into sustained market access in Brazil.

The successful path can be summarized as: Research the market → select the right products → identify a competent Brazilian partner → conduct due diligence → obtain necessary GMP certification → prepare ANVISA-compliant dossiers → secure registrations → establish competitive pricing → organize compliant logistics → build distribution → expand gradually.

 

Companies should avoid searching only for immediate purchase orders. In regulated pharmaceutical markets, the strongest opportunities arise from strategic partnerships, licensing agreements, regulatory collaboration and long-term distribution relationships. For Bangladeshi pharmaceutical companies prepared to invest in compliance, documentation, Brazilian partnerships and sustained market development, Brazil represents one of the most promising large-scale pharmaceutical export opportunities in Latin America.